{"id":71544,"date":"2026-08-03T14:45:32","date_gmt":"2026-08-03T06:45:32","guid":{"rendered":"https:\/\/flcube.com\/?p=71544"},"modified":"2026-08-03T14:45:33","modified_gmt":"2026-08-03T06:45:33","slug":"brightgenes-generic-tiotropium-bromide-inhalation-spray-gains-nmpa-approval-as-chinas-first-domestic-copd-treatment-alternative","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71544","title":{"rendered":"BrightGene&#8217;s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China&#8217;s First Domestic COPD Treatment Alternative"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>BrightGene (Suzhou) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/688166:SHA\">SHA: 688166<\/a>) announced that its <strong>tiotropium bromide inhalation spray<\/strong> has received marketing approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong>, marking the first generic version of this established chronic obstructive pulmonary disease (COPD) therapy to be approved for commercialization in the Chinese market.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-amp-product-details\" class=\"wp-block-heading\">Regulatory Milestone &amp; Product Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>BrightGene (Suzhou) Co., Ltd. (SHA: 688166)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Tiotropium bromide inhalation spray<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Maintenance treatment of COPD (chronic bronchitis and emphysema)<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>03 Aug 2026<\/td><\/tr><tr><td><strong>Originator<\/strong><\/td><td>Boehringer Ingelheim<\/td><\/tr><tr><td><strong>Market Status<\/strong><\/td><td>First generic approval in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-therapeutic-profile-amp-clinical-benefits\" class=\"wp-block-heading\">Therapeutic Profile &amp; Clinical Benefits<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Long-acting muscarinic antagonist (LAMA) providing sustained bronchodilation<\/li>\n\n\n\n<li><strong>Indication Scope:<\/strong> Maintenance treatment for chronic obstructive pulmonary disease, including chronic bronchitis and emphysema<\/li>\n\n\n\n<li><strong>Clinical Outcomes:<\/strong> Reduces frequency of acute exacerbations and improves quality of life for COPD patients<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Once-daily inhalation spray formulation for patient convenience<\/li>\n\n\n\n<li><strong>Therapeutic Validation:<\/strong> Well-established efficacy and safety profile based on extensive clinical experience with originator product<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-implications-amp-strategic-significance\" class=\"wp-block-heading\">Market Implications &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>COPD Burden in China:<\/strong> Affects an estimated 100 million adults, representing one of the country&#8217;s most significant respiratory health challenges<\/li>\n\n\n\n<li><strong>Cost Containment Opportunity:<\/strong> Generic entry expected to reduce treatment costs by 60-80% compared to originator pricing, enhancing accessibility for China&#8217;s vast COPD population<\/li>\n\n\n\n<li><strong>Complex Generic Achievement:<\/strong> Inhalation products represent technically challenging dosage forms requiring sophisticated manufacturing capabilities and bioequivalence demonstration<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> BrightGene gains first-mover advantage in China&#8217;s generic tiotropium market, potentially capturing significant market share before additional competitors enter<\/li>\n\n\n\n<li><strong>Healthcare System Impact:<\/strong> Supports China&#8217;s broader pharmaceutical cost-containment initiatives while maintaining therapeutic standards for chronic disease management<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-commercial-outlook-amp-industry-context\" class=\"wp-block-heading\">Commercial Outlook &amp; Industry Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The approval positions BrightGene as a leader in complex generic development within China&#8217;s respiratory therapeutics segment. With COPD representing a leading cause of mortality and healthcare expenditure in China, the availability of an affordable generic alternative addresses a critical public health need.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Industry analysts note that successful commercialization will depend on BrightGene&#8217;s ability to demonstrate equivalent clinical performance to the originator product, establish reliable supply chains for the specialized inhalation delivery system, and navigate potential reimbursement negotiations with provincial healthcare authorities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The timing of this approval aligns with China&#8217;s increasing emphasis on domestic pharmaceutical innovation and self-sufficiency, particularly for essential medicines addressing high-burden chronic diseases. BrightGene&#8217;s achievement demonstrates the maturation of China&#8217;s generic pharmaceutical industry capabilities in complex dosage forms previously dominated by multinational corporations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market dynamics, and commercial expectations for BrightGene&#8217;s tiotropium bromide inhalation spray. Actual results may differ due to risks including market adoption rates, competitive responses, pricing pressures, and healthcare policy changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688166_20260801_Z050.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688166_20260801_Z050.\"><\/object><a id=\"wp-block-file--media-ad22cb0c-4c7c-4f4e-b662-928f4421c31b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688166_20260801_Z050.pdf\">688166_20260801_Z050<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/688166_20260801_Z050.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ad22cb0c-4c7c-4f4e-b662-928f4421c31b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BrightGene (Suzhou) Co., Ltd. (SHA: 688166) announced that its tiotropium bromide inhalation spray has received&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[2536,42,15,1179],"class_list":["post-71544","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-brightgene-bio-medical-technology","tag-first-mover-generic","tag-product-approvals","tag-sha-688166"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BrightGene&#039;s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China&#039;s First Domestic COPD Treatment Alternative - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BrightGene (Suzhou) Co., Ltd. (SHA: 688166) announced that its tiotropium bromide inhalation spray has received marketing approval from China&#039;s National Medical Products Administration (NMPA), marking the first generic version of this established chronic obstructive pulmonary disease (COPD) therapy to be approved for commercialization in the Chinese market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71544\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BrightGene&#039;s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China&#039;s First Domestic COPD Treatment Alternative\" \/>\n<meta property=\"og:description\" content=\"BrightGene (Suzhou) Co., Ltd. (SHA: 688166) announced that its tiotropium bromide inhalation spray has received marketing approval from China&#039;s National Medical Products Administration (NMPA), marking the first generic version of this established chronic obstructive pulmonary disease (COPD) therapy to be approved for commercialization in the Chinese market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71544\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T06:45:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-03T06:45:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71544#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71544\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BrightGene&#8217;s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China&#8217;s First Domestic COPD Treatment Alternative\",\"datePublished\":\"2026-08-03T06:45:32+00:00\",\"dateModified\":\"2026-08-03T06:45:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71544\"},\"wordCount\":461,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"BrightGene Bio-Medical Technology\",\"First-mover generic\",\"Product approvals\",\"SHA: 688166\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71544#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71544\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71544\",\"name\":\"BrightGene's Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China's First Domestic COPD Treatment Alternative - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-03T06:45:32+00:00\",\"dateModified\":\"2026-08-03T06:45:33+00:00\",\"description\":\"BrightGene (Suzhou) Co., Ltd. (SHA: 688166) announced that its tiotropium bromide inhalation spray has received marketing approval from China's National Medical Products Administration (NMPA), marking the first generic version of this established chronic obstructive pulmonary disease (COPD) therapy to be approved for commercialization in the Chinese market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71544#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71544\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71544#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BrightGene&#8217;s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China&#8217;s First Domestic COPD Treatment Alternative\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BrightGene's Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China's First Domestic COPD Treatment Alternative - Insight, China&#039;s Pharmaceutical Industry","description":"BrightGene (Suzhou) Co., Ltd. (SHA: 688166) announced that its tiotropium bromide inhalation spray has received marketing approval from China's National Medical Products Administration (NMPA), marking the first generic version of this established chronic obstructive pulmonary disease (COPD) therapy to be approved for commercialization in the Chinese market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71544","og_locale":"en_US","og_type":"article","og_title":"BrightGene's Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China's First Domestic COPD Treatment Alternative","og_description":"BrightGene (Suzhou) Co., Ltd. (SHA: 688166) announced that its tiotropium bromide inhalation spray has received marketing approval from China's National Medical Products Administration (NMPA), marking the first generic version of this established chronic obstructive pulmonary disease (COPD) therapy to be approved for commercialization in the Chinese market.","og_url":"https:\/\/flcube.com\/?p=71544","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-03T06:45:32+00:00","article_modified_time":"2026-08-03T06:45:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71544#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71544"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BrightGene&#8217;s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China&#8217;s First Domestic COPD Treatment Alternative","datePublished":"2026-08-03T06:45:32+00:00","dateModified":"2026-08-03T06:45:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71544"},"wordCount":461,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["BrightGene Bio-Medical Technology","First-mover generic","Product approvals","SHA: 688166"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71544#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71544","url":"https:\/\/flcube.com\/?p=71544","name":"BrightGene's Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China's First Domestic COPD Treatment Alternative - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-03T06:45:32+00:00","dateModified":"2026-08-03T06:45:33+00:00","description":"BrightGene (Suzhou) Co., Ltd. (SHA: 688166) announced that its tiotropium bromide inhalation spray has received marketing approval from China's National Medical Products Administration (NMPA), marking the first generic version of this established chronic obstructive pulmonary disease (COPD) therapy to be approved for commercialization in the Chinese market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71544#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71544"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71544#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BrightGene&#8217;s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China&#8217;s First Domestic COPD Treatment Alternative"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71544"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71544\/revisions"}],"predecessor-version":[{"id":71547,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71544\/revisions\/71547"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}